HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M300498-JLR200v1 45/7/1207    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhat, S. Articles by Sorci-Thomas, M. G. Search for Related Content PubMed PubMed Citation Articles by Bhat, S. Articles by Sorci-Thomas, M. G. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 45, 1207-1220, July 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Quality control in the apoA-I secretory pathway

Shaila Bhat^1,*, Manal Zabalawi^1,*, Mark C. Willingham^*, Gregory S. Shelness^*, Michael J. Thomas and Mary G. Sorci-Thomas^2,*,

^* Departments of Pathology, Wake Forest University Health Sciences, Winston-Salem, NC
Biochemistry, Wake Forest University Health Sciences, Winston-Salem, NC

² To whom correspondence should be addressed. e-mail: msthomas{at}wfubmc.edu

Manuscript received 3 December 2003, in revised form 11 March 2004, re-revised form 25 March 2004, and in re-re-revised form 30 March 2004.

From a total of 47 known apolipoprotein A-I (apoA-I) mutations, only 18 are linked to low plasma HDL apoA-I concentrations, and 78% of these map to apoA-I helices 6 and 7 (residues 143–186). Gene transfer and transgenic mouse studies have shown that several helix 6 apoA-I mutations have reduced hepatic HDL production. Our objective was to examine the impact of helix 6 modifications on intracellular biosynthetic processing and secretion of apoA-I. Cells were transfected with wild-type or mutant apoA-I, radiolabeled with [³⁵S]Met/Cys, and then placed in unlabeled medium for up to 4 h. Results show that >90% of newly synthesized wild-type apoA-I was secreted by 60 min. Over the same length of time, only 20% of helix 6 deletion mutant (6 apoA-I) was secreted, whereas 80% remained cell associated. Microscopic and biochemical studies revealed that cell-associated 6 apoA-I was located predominantly within the cytoplasm as lipid-protein inclusions, whereas wild-type apoA-I was localized in the endoplasmic reticulum/Golgi. Results using other helix deletions or helix 6 substitution mutations indicated that only complete removal of helix 6 resulted in massive cytoplasmic accumulation.

These data suggest that alterations in native apoA-I conformation can lead to aberrant trafficking and accumulation of apolipoprotein-phospholipid structures. Thus, conformation-dependent alterations in intracellular trafficking and turnover may underlie the reduced plasma HDL concentrations observed in individuals harboring deletion mutations within helix 6.

Supplementary key words apolipoprotein A-I • high density lipoprotein • mutant apolipoprotein A-I • protein secretion • quality control pathway • aggresomes • aggregation • endoplasmic reticulum • Golgi • nuclear envelope • immunofluorescence

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. S. Owen, M. S. Bharadwaj, M. J. Thomas, S. Bhat, M. P. Samuel, and M. G. Sorci-Thomas Ratio determination of plasma wild-type and L159R apoA-I using mass spectrometry: tools for studying apoA-IFin J. Lipid Res., January 1, 2007; 48(1): 226 - 234. [Abstract] [Full Text] [PDF]